Siga’s Smallpox Win is No Monkey Business!
On May 19, 2022, The Siga Technologies, Inc. (NASDAQ: SIGA) announced the approval of its intravenous (IV) formulation of TPOXX® (tecovirimat) by the U.S. Food and Drug Administration (FDA). The drug is intended to treat smallpox, and the approval offers a much-needed alternative to those...
